ACSL6 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1247012	0.73	3/20
SCHEMBL9413588	0.62	3/20
SCHEMBL10614660	0.58	3/20
SCHEMBL9648991	0.57	3/20
SCHEMBL8642144	0.55	3/20
Trifluoroacetic Acid (SCHEMBL1794473)	0.55	3/20
Trifluoroacetic Acid (SCHEMBL1796405)	0.55	3/20
SCHEMBL11137941	0.53	3/20
SCHEMBL7046750	0.51	3/20
SCHEMBL9811274	0.51	3/20
SCHEMBL6240234	0.49	3/20
SCHEMBL9834510	0.48	3/20
SCHEMBL9836010	0.48	3/20
SCHEMBL11145408	0.47	3/20
SCHEMBL11067358	0.47	3/20
SCHEMBL10944403	0.46	3/20
SCHEMBL12930824	0.46	3/20
SCHEMBL3367530	0.46	3/20
Hydrochloric Acid (SCHEMBL8900021)	0.46	3/20
Acetic Acid (SCHEMBL3368203)	0.46	3/20

Clinical trials — most relevant to ACSL6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia	PHASE3	COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC	PHASE1/PHASE2	UNKNOWN
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease	EARLY_PHASE1	COMPLETED
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Familial Partial Lipodystrophy Study	nan	COMPLETED
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise	nan	COMPLETED
Androgens and NAFLD Longitudinal Cohort Study	nan	RECRUITING
Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing	nan	COMPLETED
Lifestyle Intervention in Preparation for Pregnancy (LIPP)	nan	COMPLETED
The Roles of SAH Gene Family in Athrogenic Dyslipidemia in Postmenopausal Women	nan	UNKNOWN
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Role of Dairy Products in Weight Maintenance	nan	COMPLETED
Genetic-specific Effects of Fructose on Liver Lipogenesis	nan	COMPLETED
Dietary Fatty Acids, PPAR Activated Genes, and CHD	nan	COMPLETED
Effect of Dietary SFA and Fructose on Hepatic Insulin Sensitivity	nan	COMPLETED
Exercise Intolerance Study in Long Chain Fatty Acid Oxidation Disorders	nan	RECRUITING
Gene Expression in Obesity and Insulin Resistance	nan	COMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN)	nan	COMPLETED
Omega-3 vs Very Low Calorie Diet for Liver Size Reduction	nan	UNKNOWN
Acute Fatty Acid Intervention Study (AFAST)	nan	COMPLETED
Action of Essential Fatty Acids on the Expression of Antioxidant Genes and Athletic Performance	nan	COMPLETED
Personalized or Precision Medicine in the Dietary Approach to Obesity	nan	UNKNOWN
Systemic Biomarkers of Brain Injury From Hyperammonemia	nan	RECRUITING
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Metabolic Effects of Medium-Chain Fatty Acids in Patients With Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Healthy Individuals	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a ACSL6 binder may also engage these)

Protein	Name	Similarity
Q91WC3	—	1.000	Q91WC3 →
P33124	—	0.992	P33124 →
ACSL1	Long-chain-fatty-acid--CoA ligase 1	0.975	landscape →
P18163	—	0.963	P18163 →
P41216	—	0.962	P41216 →
Q9JID6	—	0.959	Q9JID6 →
Q5I0K3	—	0.947	Q5I0K3 →
Q8R4N0	—	0.946	Q8R4N0 →
Q8BGA8	—	0.945	Q8BGA8 →
Q9QZ08	—	0.945	Q9QZ08 →
Q924H5	—	0.945	Q924H5 →
O43502	—	0.944	O43502 →
A3QK15	—	0.943	A3QK15 →
Q6AYT9	—	0.943	Q6AYT9 →
Q8R2J9	—	0.942	Q8R2J9 →
Q4R4D5	—	0.942	Q4R4D5 →
Q8R127	—	0.942	Q8R127 →
Q6NUN0	—	0.941	Q6NUN0 →
CTH	Cystathionine gamma-lyase	0.941	landscape →
Q8K183	—	0.941	Q8K183 →
P27119	—	0.941	P27119 →
Q8N0X4	—	0.941	Q8N0X4 →
Q7TN78	—	0.940	Q7TN78 →
Q80W40	—	0.940	Q80W40 →
P81799	—	0.940	P81799 →
Q9UJ70	—	0.939	Q9UJ70 →
P61922	—	0.939	P61922 →
Q811P6	—	0.939	Q811P6 →
P27117	—	0.939	P27117 →
Q5RFI8	—	0.939	Q5RFI8 →